This study represents an important step toward the development of alternative therapies for patients with ELANE mutations, particularly those who respond poorly to G-CSF and are at increased risk of progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Here, ELANE is linked to myelodysplastic syndrome.